Case Study · Pharmaceutical

Can a brand outspent ten to one still win a U.S. launch? Yes, on precision rather than volume.

Two months into launch, paid search alone drove more than $6,000,000 in attributed revenue, the integrated program returned $8.65 for every media dollar invested, and positive physician sentiment rose 200 percent.

RocketSauce Media Labs20266 min read

A U.S. drug launch is largely decided in its first year. Awareness, access, and prescribing habits harden early, and the brands that already hold physician attention spend heavily to keep holding it. Our client entered that market from behind, launching a treatment for Crohn's disease and ulcerative colitis with almost no U.S. corporate brand recognition against category leaders outspending it by more than ten to one.

The audience made the gap harder. Health care providers, or HCPs, are cautious by professional design. Moving a stable patient off a therapy that is working carries clinical risk, so adoption of a new drug depends on trust built over months of repeated, credible exposure. Volume of impressions has very little to do with it.

So the pharmaceutical media strategy for this launch started with competitive spend analysis rather than a channel wish list. We mapped where the leading branded competitors were concentrating their dollars, identified the HCP segments most likely to shift patients, and built the plan around what that mapping exposed.

The challenge

• Limited brand equity. U.S. awareness of the client as a corporate brand trailed established competitors by a wide margin, which meant the product had to earn credibility for itself and for the company behind it at the same time.
• A spend disadvantage of more than ten to one. Major competitors were buying at a media weight the client had no realistic path to match in the launch year.
• Entrenched prescribing habits. HCPs are reluctant to move patients off therapies that are already effective, which makes new-drug adoption slow and dependent on peer validation.

The approach

Channel selection followed the competitive gaps. A review of competitive investment showed the leading branded competitors concentrated overwhelmingly in Network, Broadcast, Cable, and Syndication television. Every major player was bidding for the same broadcast real estate. We put the client's investment into digital instead: paid search, programmatic display, endemic and custom media, and peer-to-peer. Those were the channels with the lowest competitive noise and the highest precision, measurability, and return.

Targeting was ranked by patient-shift potential. Rather than treating all gastroenterologists as one audience, we prioritized HCPs by how likely their patient panel was to move. Infliximab prescribers came first, then prescribers treating ulcerative pancolitis, Crohn's disease, and comparator drugs, then ulcerative pancolitis prescribers.

Endemic media and EHR placements covered both trust and workflow. Endemic channels are the trade publications and clinical sites physicians already read and believe. EHR, the electronic health record system, is where they actually work. Endemic and custom placements built category-relevant credibility, print and digital insertions in top trade titles reinforced it, and EHR placements reached HCPs at the moment of diagnosis and treatment decision. The EHR buy also sharpened measurement across the whole program.

Peer-to-peer channels carried the credibility argument. Physicians weigh the opinion of other physicians more heavily than any advertisement. We used gated peer-to-peer and HCP-only environments to place the brand inside conversations where treatment decisions were already being debated.

Paid search captured and widened active intent. Search reached the handraisers, meaning the HCPs researching ulcerative colitis and Crohn's disease treatment options in that moment, then expanded reach among physicians already open to reviewing alternatives.

Frequency stayed consistent for the full launch year. We planned sustained weight across the calendar so the brand accumulated recognition month over month, and we kept the flexibility to move spend between channels in-flight as performance data arrived.

Every channel and tactic was tagged. Endemic partners delivered NPI-level reporting, which let us tie activity back to prescriber segments and report on the program as one funnel rather than a set of separate media buys.

The results

Two months into launch, with only paid search live, the performance data was already confirming the plan.

Measure	Result
Impressions	5,620,733
Clicks to the website	61,000+
Attributed revenue	$6,000,000+
Total brand mentions	175,800, up 13%
Brand news mentions	1,574, up 114%
Positive patient and caregiver sentiment	Up 307%
Positive HCP sentiment	Up 200%
Returned per media dollar, full program	$8.65

The sentiment movement is the part worth sitting with. Positive patient and caregiver sentiment climbed 307 percent while competitor sentiment held flat or slipped, and positive HCP sentiment climbed 200 percent while competitor HCP sentiment fell sharply across the category. That pattern is what a coordinated omnichannel program produces. Physicians encountered the brand in the trade press they trust, in the EHR at the point of care, in peer conversation, and in search results when they went looking, and each exposure reinforced the last instead of arriving as an unrelated impression.

When you cannot buy more attention than the competition, you have to buy better attention. That requires knowing exactly which physicians can move patients, and exactly where those physicians are willing to listen.

---

Four principles behind the work

Find the whitespace before you write the plan. Competitive spend analysis is not a slide at the back of a deck. In this launch it determined the entire channel mix, because the category leaders had concentrated their weight in broadcast and left digital comparatively open.

Rank the audience by what it can actually change. Reaching more HCPs matters less than reaching the HCPs whose patient panels are most likely to shift. Prescriber-level data made that ranking possible before the first dollar was spent.

Launch across the full funnel from day one. Physicians arrive at different stages of familiarity with a new therapy, and a plan that assumes everyone starts at awareness wastes the ones who are already evaluating options.

Tag it or you cannot defend it. Measurement discipline is what turned in-flight optimization from an argument into a decision, and it is what allowed the program to report revenue rather than activity.

Why we work this way

RocketSauce is senior-staffed on purpose. The people who built this pharmaceutical media strategy are the people who ran it, which is how a competitive spend read in month one becomes a channel decision in month two rather than a deck that circulates until the launch window closes. Pharma marketing carries regulatory nuance, complex HCP behavior, and a fragmented channel landscape, and working through that requires a small team of experienced practitioners in the account daily. RSML operates as an extension of the client's team, is transparent about fees and results, and reports against revenue.